Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 350 publications.

Anderson SA, Bian B, Talbird SE, Stratton M, Maxwell R, Ferries R. Medical cost and healthcare resource utilization offset for zuranolone relative to SSRIs in the treatment of postpartum depression. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Citrome L, Sajatovic M. Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder. BMC Psychiatry. 2024 Sep 10;24(1):605. doi: 10.1186/s12888-024-06034-

Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.

Sweeney C, Calingaert B, Holzmann R, Moeller C, Schomakers G, Sok A, Pisa F, Gilsenan A. Physician knowledge of safe use of cyproterone acetate monotherapies and meningioma. Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):300. doi: 10.1002/pds.5687

DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882

DiBenedetti D, Huang M-Y, Kosa K, Suthoff E, Bonthapally V, Lasser R, Pollack M, Doherty J, Mak C, Cutler AJ, Mattingly GW. Assessing individuals' experiences with zuranolone for major depressive disorder: qualitative interviews with participants from the open-label shoreline study. Poster presented at the 2023 ASCP Annual Meeting; May 31, 2023. Miami Beach, FL.

Doane MJ, Boeri M, Vass C, Bussberg C, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia or bipolar I disorder. Poster presented at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; May 30, 2023. Miami Beach, FL.

Doane MJ, Boeri M, Vass CM, Bussberg CJ, Panchmatia HR, Gasper S, Citrome L, Sajatovic M. Preferences for characteristics of oral antipsychotic treatments: survey results of patients living with schizophrenia. Poster presented at the SIRS 2023 Congress; May 13, 2023. Toronto, Canada.

Forns J, Dudukina E, Hagg D, Szentkuti P, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Ehrenstein V, Reutfors J, Rebordosa C. Risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in Denmark and Sweden: a population-based cohort study. Neurol Ther. 2022 Dec 1;11(4):1659-76. doi: 10.1007/s40120-022-00396-y

Huang MY, Smith A, Brister T, Counts N, Sweeney C, McSorley D, Suthoff E, Parikh S. Report from a national survey of depression treatment: patient experience on antidepressant medications for major depressive disorder. Poster presented at the AMCP Nexus 2022; October 11, 2022. National Harbor, MD. [abstract] J Manag Care Pharm. 2022 Oct; 28(10-a):S59-60.

Huang MY, Counts N, Smith A, Brister T, Sweeney C, McSorley D, Suthoff E, Parikh S. Perspectives on the unmet need in the treatment of major depressive disorder: results from a patient survey. Poster presented at the Psych Congress 2022; September 17, 2022. New Orleans, LA.

Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman B, Garcia de Albaniz X. The effect of the anticholinergic properties of antidepressants on the incidence of dementia: a target trial emulation. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Forns J. Is the exposure to environmental pollutants such a perfluoroalkyl substances a risk factor for ADHD? Presented at the 2021 8th World Congress on ADHD Virtual Event; May 8, 2021.

Forns J, Dudukina E, Hagg D, Szentkuti EP, Gembert K, Plana E, Gilsenan A, Horvath-Puho E, Reutfors J, Rebordosa C. Cohort study of the incidence of major cardiovascular events in new adult users of lisdexamfetamine and remote adult users of other attention-deficit/hyperactivity disorder treatments. Poster presented at the 2021 8th World Congress on ADHD Virtual Event; May 6, 2021.

Brockbank J, Krause T, Moss E, Pedersen AM, Morup MF, Ahdesmaki O, Vaughan J, Brodtkorb T-H. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes. 2021 Mar 18;19(1):94. doi: 10.1186/s12955-021-01723-x

McIntyre RS, Patel MD, Masand PS, Harrington A, Gillard P, McElroy SL, Sullivan K, Montano CB, Brown TM, Nelson L, Jain R. The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder. Curr Med Res Opin. 2021 Jan;37(1):135-44. doi: 10.1080/03007995.2020.1860358

Starr HL, Abell J, Larish A, Lewis S, DeMuro C, Gogate J, Jamieson C, Daly E, Zaki N, Kramer M. Self-reported review of the value of esketamine in patients with treatment-resistant depression: understanding the patient experience in the STRIVE Study. Psychiatry Research. 2020 Nov;293:113376. doi: 10.1016/j.psychres.2020.113376

Weiss C, Meehan S, Brown TM, Gupta C, DiBenedetti D, Thase M, McIntyre R, Ismail Z. Exploring patient experiences taking adjunctive brexpiprazole for major depressive disorder (MDD): post-hoc analysis of exit interview data. Poster presented at the 2019 32nd Annual Psychiatric & Mental Health Congress; October 2019. San Diego, CA.

Doherty K, Marcano-Belisario J, Cohn M, Mastellos N, Morrison C, Car J, Doherty G. Engagement with mental health screening on mobile devices: results from an antenatal feasibility study. Poster presented at the 2019 CHI Conference on Human Factors in Computing Systems; May 2019. Glasgow, Scotland. doi: 10.1145/3290605.3300416

Rivas I, Basagana X, Cirach M, Lopez-Vicente M, Suades-Gonzalez E, Garcia-Esteban R, Alvarez-Pedrerol M, Dadvand P, Sunyer J. Association between early life exposure to air pollution and working memory and attention. Environ Health Perspect. 2019 May;127(5):57002. doi: 10.1289/EHP3169

Lenters V, Iszatt N, Forns J, Cechova E, Kocan A, Legler J, Leonards P, Stigum H, Eggesbo M. Early-life exposure to persistent organic pollutants (OCPs, PBDEs, PCBs, PFASs) and attention-deficit/hyperactivity disorder: a multi-pollutant analysis of a Norwegian birth cohort. Environ Int. 2019 Apr;125:33-42. doi: 10.1016/j.envint.2019.01.020

Ferrer M, Garcia-Esteban R, Iniguez C, Costa O, Fernandez-Somoano A, Rodríguez-Delhi C, Ibarluzea J, Lertxundi A, Tonne C, Sunyer J, Julvez J. Head circumference and child ADHD symptoms and cognitive functioning: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2019 Mar;28(3):377-88. doi: 10.1007/s00787-018-1202-4

Doherty K, Barry M, Marcano-Belisario J, Arnaud B, Morrison C, Car J, Doherty G. A mobile app for the self-report of psychological well-being during pregnancy (BrightSelf): qualitative design study. JMIR Mhealth Uhealth. 2018 Nov 27;5(4):e10007. doi: 10.2196/10007

Forns J, Sunyer J, Garcia-Esteban R, Porta D, Ghassabian A, Giorgis-Allemand L, Gong T, Gehring U, Sorensen M, Standl M, Sugiri D, Almqvist C, Andiarena A, Baldaloni C, Beelen R, Berdel D, Cesaroni G, Charles MA, Eriksen KT, Estarlich M, Fernandez MF, Forhan A, Jaddoe VWV, Korek M, Lichtenstein P, Lertxundi A, Lopez-Espinosa MJ, Markevych I, de Nazelle A, Raaschou-Nielsen O, Nieuwenhuijsen M, Perez-Lobato R, Philippat C, Slama R, Tiesler CM, Verhulst FC, von Berg A, Vrijkotte T, Nybo Andersen AM, Heude B, Kramer U, Heinrich J, Tiemeier H, Forastiere F, Pershagen G, Brunekreef B, Guxens M. Air pollution exposure during pregnancy and symptoms of attention deficit and hyperactivity disorder in children in Europe. Epidemiology. 2018 Sep;29(5):618-26. doi: 10.1097/EDE.0000000000000874

Brain C, Kymes S, DiBenedetti DB, Brevig T, Velligan DI. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry. 2018 Aug 13;18(1):253. doi: 10.1186/s12888-018-1833-5

Forns J, Stigum H, Hoyer BB, Sioen I, Sovcikova E, Nowack N, Lopez-Espinosa MJ, Guxens M, Ibarluzea J, Torrent M, Wittsiepe J, Govarts E, Trnovec T, Chevrier C, Toft G, Vrijheid M, Iszatt N, Eggesbo M. Prenatal and postnatal exposure to persistent organic pollutants (POPs) and attention-deficit and hyperactivity disorder (ADHD): a pooled analysis of seven European birth cohort studies. Int J Epidemiol. 2018 Aug;47(4):1082-97. doi: 10.1093/ije/dyy052

Brain C, Kymes S, DiBenedetti D, Kelnaes AM, Brevig T, Velligan DL. Assessing experiences, attitudes, and perceptions associated with treatment-resistant schizophrenia (TRS): caregiver focus groups. Poster presented at the 2018 Annual Meeting of the American Psychiatric Association; May 8, 2018. New York, NY.

Gascon M, Sanchez-Benavides G, Dadvand P, Martinez D, Gramunt N, Gotsens X, Cirach M, Vert C, Molinuevo JL, Crous-Bou M, Nieuwenhuijsen M. Long-term exposure to residential green and blue spaces and anxiety and depression in adults: a cross-sectional study. Environ Res. 2018 Apr;162:231-9. doi: 10.1016/j.envres.2018.01.012

Imagawa H, Nagar SP, Montgomery W, Nakamura T, Sato M, Davis KL. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatr Dis Treat. 2018 Feb 22;14:611-21. doi: 10.2147/NDT.S150261

Delacretaz A, Lagares Santos P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. Pharmacogenet Genomics. 2017 Dec 1;27(12):464-72. doi: 10.1097/FPC.0000000000000313

Kawai K, Kawai AT, Wollan P, Yawn BP. Adverse impacts of chronic pain on health-related quality of life, work productivity, depression and anxiety in a community-based study. Fam Pract. 2017 Nov 16;34(6):656-61. doi: 10.1093/fampra/cmx034

Mortamais M, Pujol J, van Drooge BL, Macia D, Martinez-Vilavella G, Reynes C, Sabatier R, Rivas I, Grimalt J, Forns J, Alvarez-Pedrerol M, Querol X, Sunyer J. Effect of exposure to polycyclic aromatic hydrocarbons on basal ganglia and attention-deficit hyperactivity disorder symptoms in primary school children. Environ Int. 2017 Aug;105:12-9. doi: 10.1016/j.envint.2017.04.011

Novick D, Montgomery W, Treuer T, Koyanagi A, Aguado J, Kraemer A, Haro JM. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder. Patient Prefer Adherence. 2017 Jun 6;11:1019-25. doi: 10.2147/PPA.S124581

Chirila C, Nuamah I, Woodruff K. Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials. Curr Med Res Opin. 2017 Jun;33(6):1083-90. doi: 10.1080/03007995.2017.1300144

Francois C, Nielsen R, Danchenko N, Williams V, Lancon C. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. Curr Med Res Opin. 2017 Jun;33(6):1057-66. doi: 10.1080/03007995.2017.1299701

Herman BK, Deal LS, Kando JC, DiBenedetti DB, Nelson L, Fehnel SE, Brown TM. The use and value of the 7-item binge eating disorder screener in clinical practice. Prim Care Companion CNS Disord. 2017 Jun;19(3):16m02075.

Marcano Belisario JS, Doherty K, O'Donoghue J, Ramchandani P, Majeed A, Doherty G, Morrison C, Car J. A bespoke mobile application for the longitudinal assessment of depression and mood during pregnancy: protocol of a feasibility study. BMJ Open. 2017 May 29;7(5):e014469. doi: 10.1136/bmjopen-2016-014469

Suades-Gonzalez E, Forns J, Garcia-Esteban R, Lopez-Vicente M, Esnaola M, Alvarez-Pedrerol M, Julvez J, Caceres A, Basagana X, Lopez-Sala A, Sunyer J. A longitudinal study on attention development in primary school children with and without teacher-reported symptoms of ADHD. Front Psychol. 2017 May 16;8:655. doi: 10.3389/fpsyg.2017.00655

Marcano-Belisario JS, Gupta AK, O'Donoghue J, Ramchandani P, Morrison C, Car J. Implementation of depression screening in antenatal clinics through tablet computers: results of a feasibility study. BMC Med Inform Decis Mak. 2017 May 10;17(1):59. doi: 10.1186/s12911-017-0459-8

Barry M, Doherty K, Marcano-Belisario J, Car J, Morrison C, Doherty G. mHealth for maternal mental health: everyday wisdom in ethical design. Poster presented at the 2017 CHI Conference on Human Factors in Computing Systems; May 2017. Denver, CO.

Beillat M, Brown TM, DiBenedetti DB, Naber D. Patient and caregiver perspectives on the Heinrichs-Carpenter Quality of Life Scale and the Subjective Well-being Under Neuroleptics-Short Form. J Psychiatry Psychiatric Disord. 2017 May;1(3):109-26.

Nagar SP, Sato M, Montgomery W, Nakamura T, Imagawa H, Davis KL. Treatment patterns and characteristics of adult patients with attention deficit/hyperactivity disorder receiving atomoxetine in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A305.

Wilkinson A, Anderson S, Wheeler SB. Screening for and treating postpartum depression and psychosis: a cost-effectiveness analysis. Matern Child Health J. 2017 Apr;21(4):903-14. doi: 10.1007/s10995-016-2192-9

Camprodon-Rosanas E, Ribas-Fito N, Batlle S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Association between sluggish cognitive tempo symptoms and attentional network and working memory in primary schoolchildren. J Atten Disord. 2017 Apr 1. doi: 10.1177/1087054717702245

Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039

Novick D, Montgomery W, Aguado J, Peng X, Haro JM. Factors associated with and impact of pain persistence in Asian patients with depression: a 3-month, prospective observational study. Int J Psychiatry Clin Pract. 2017 Mar;21(1):29-35. doi: 10.1080/13651501.2016.1242751

Triguero-Mas M, Gidlow CJ, Martinez D, de Bont J, Carrasco-Turigas G, Martinez-Iniguez T, Hurst G, Masterson D, Donaire-Gonzalez D, Seto E, Jones MV, Nieuwenhuijsen MJ. The effect of randomised exposure to different types of natural outdoor environments compared to exposure to an urban environment on people with indications of psychological distress in Catalonia. PLoS One. 2017 Mar 1;12(3):e0172200.

Boucher O, Julvez J, Guxens M, Arranz E, Ibarluzea J, Sanchez de Miguel M, Fernandez-Somoano A, Tardon A, Rebagliato M, Garcia-Esteban R, O’Connor G, Ballester F, Sunyer J. Association between breastfeeding duration and cognitive development, autistic traits and ADHD symptoms: a multicenter study in Spain. Pediatr Res. 2017 Mar;81(3):434-42. doi: 10.1038/pr.2016.238

Llorca PM, Lancon C, Hartry A, Brown TM, DiBenedetti DB, Kamat SA, Francois C. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry. 2017 Feb 13;17:67. doi: 10.1186/s12888-017-1213-6

Vandenberghe F, Saigi-Morgui N, Delacretaz A, Quteineh L, Crettol S, Ansermot N, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. Pharmacogenet Genomics. 2016 Dec;26(12):547-57. doi: 10.1097/FPC.0000000000000249